It's not quite the same since a biotech will often have a patent-enforced monopoly which generates zero-risk profits after the uncertain FDA approval process. T

It's not quite the same since a biotech will often have a patent-enforced monopoly which generates zero-risk profits after the uncertain FDA approval process. These companies usually get acquired quickly after their drugs hit the market